✦ LIBER ✦

A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease

✍ Scribed by Elliott Vichinsky; Onyinye Onyekwere; John Porter; Paul Swerdlow; James Eckman; Peter Lane; Beatrice Files; Kathryn Hassell; Patrick Kelly; Felicia Wilson; Françoise Bernaudin; Gian Luca Forni; Iheanyi Okpala; Catherine Ressayre-Djaffer; Daniele Alberti; Jaymes Holland; Peter Marks; Ellen Fung; Roland Fischer; Brigitta U. Mueller; Thomas Coates; the Deferasirox in Sickle Cell Investigators

Book ID: 108674106
Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 547 KB
Volume: 136
Category: Article
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.2006.06455.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Deferasirox administration for the treat

Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia

✍ Vassilis Ladis; Helen Berdousi; Efstathios Gotsis; Antonis Kattamis 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB

Long-term safety and efficacy of deferas

Long-term safety and efficacy of deferasirox (Exjade®) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease

✍ Elliott Vichinsky; Françoise Bernaudin; Gian Luca Forni; Renee Gardner; Kathryn 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 305 KB

Increased prevalence of iron-overload as

Increased prevalence of iron-overload associated endocrinopathy in thalassaemia versus sickle-cell disease

✍ Ellen B. Fung; Paul R. Harmatz; Phillip D.K. Lee; Meredith Milet; Rita Bellevue; 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 108 KB

A phase 1/2, dose-escalation trial of de

A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis

✍ Pradyumna Phatak; Pierre Brissot; Mark Wurster; Paul C Adams; Herbert L. Bonkovs 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 391 KB 👁 1 views

Hereditary hemochromatosis (HH) is characterized by increased intestinal iron absorption that may result in iron overload. Although phlebotomy is widely practiced, it is poorly tolerated or contraindicated in patients with anemias, severe heart disease, or poor venous access, and compliance can vary

Australian guidelines for the assessment

Australian guidelines for the assessment of iron overload and iron chelation in transfusion-dependent thalassaemia major, sickle cell disease and other congenital anaemias

✍ P. J. Ho; L. Tay; R. Lindeman; L. Catley; D. K. Bowden 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 135 KB

Morbidity and mortality in chronically t

Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: A report from the multi-center study of iron overload

✍ Ellen B. Fung; Paul Harmatz; Meredith Milet; Samir K. Ballas; Laura De Castro; W 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 190 KB 👁 2 views

## Abstract A natural history study was conducted in 142 Thalassemic (Thal), 199 transfused Sickle Cell Disease (Tx‐SCD, __n__ = 199), and 64 non‐Tx‐SCD subjects to describe the frequency of iron‐related morbidity and mortality. Subjects recruited from 31 centers in the US, Canada or the UK were si